VBI Vaccines has appointed Damian Braga to Board of Directors to bring broad commercial expertise to support VBI's regulatory-stage trivalent hepatitis B vaccine, Sci-B-Vac.
FREMONT, CA: Commercial-stage biopharmaceutical company, VBI Vaccines Inc. has appointed Damian Braga to its Board of Directors. Braga has spent more than 25 years at Sanofi Pasteur, the human vaccines business of Sanofi Group, as the Senior Vice President, Global Commercial Operations & President, U.S., and the Americas. He was responsible for overseeing the development and execution of the commercial strategy for all late-stage products for Sanofi Pasteur's Global Vaccine Business.
Damian has been a commercial leader in the vaccine space with extensive experience successfully navigating this highly-regulated and dynamic environment. VBI Vaccines is thrilled to welcome Damian into the team with his years of expertise. He owns a track record of delivering long-term revenue and profitable growth. His understanding of public health legislation and policy issues affecting the industry and his relationship with key opinion leaders, policymakers, government officials, and other industry representatives makes him an instrumental director for the company. With Damian's expertise, VBI Vaccines prepares for the potential future commercial launch of Sci-B-Vac®.
Damian Braga has worked with VBI for the past several months as a commercial advisor and is immensely excited to join the Board at such a transformational and pivotal time. Braga believes that Sci-B-Vac® has the potential to address a real unmet public health need in the prophylactic hepatitis B space. He is excited to work with his fellow directors to guide VBI's efforts as the team prepares for regulatory and public health discussions, ensuring the company is ready for commercialization.
VBI Vaccines Inc. is a commercial-stage biopharmaceutical organization developing the next-gen of vaccines to address unmet requirements in infectious disease and immuno-oncology. The company is advancing the treatment and prevention of hepatitis B, with the only trivalent hepatitis B vaccine, Sci-B-Vac®. VBI's lead eVLP programs comprise a vaccine immunotherapeutic candidate targeting glioblastoma and a prophylactic CMV vaccine candidate.